Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450118 | 0.88 | CES2 (0.46) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL7521569 | 0.84 | CES2 (0.48) | NPC1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL8893245 | 0.80 | ELANE (0.45) | NPC1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL481549 | 0.80 | LMNA (0.49) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL240655 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL29721865 | 0.80 | KDM4E (0.50) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL680046 | 0.80 | KDM4E (0.50) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL11865903 | 0.79 | CES2 (0.46) | NPC1RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL12052657 | 0.79 | ALDH1A1 (0.49) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL28667662 | 0.79 | CES2 (0.39) | NPC1RAB9ASMN1; SMN2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352732-B1 | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GMBH (DE) | 2013-02-20 | — | — | EP | claimed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-111825611-B | 4(1H) -quinovone derivatives and uses thereof | 刘扶东 | 2022-09-09 | — | — | CN | disclosed |
| CN-114945572-A | HBF pharmacological inducing compounds for the treatment of sickle cell anemia and beta-thalassemia | 刘扶东 | 2022-08-26 | — | — | CN | disclosed |
| EP-2585451-B1 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER IP GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| EP-1760069-B1 | PROCESS FOR PRODUCING AROMATIC CARBONATE | ASAHI KASEI CHEMICALS CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2585451-A2 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | Bayer Intellectual Property GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| EP-0673931-A1 | Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-27 | — | — | EP | disclosed |
| EP-0461274-B1 | PROCESS FOR CONTINUOUSLY PRODUCING AROMATIC CARBONATE | ASAHI CHEMICAL IND (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5210268-A | Ester interchange, catalysis | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0461274-A1 | PROCESS FOR CONTINUOUSLY PRODUCING AROMATIC CARBONATE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-12-18 | — | — | EP | disclosed |
| EP-0276204-A2 | Pyridine gametocides | Monsanto Company (US) | 1988-07-27 | — | — | EP | disclosed |
| US-4642349-A | REACTING AROMATIC CARBONATE AND ORGANIC HALIDE | THE DOW CHEMICAL COMPANY (US) | 1987-02-10 | — | — | US | disclosed |
| US-4612386-A | Process for making esters | THE DOW CHEMICAL COMPANY (US) | 1986-09-16 | — | — | US | disclosed |
| US-4375549-A | FROM ORGANIC SILYL HALIDE AND A CARBONATE | THE DOW CHEMICAL COMPANY (US) | 1983-03-01 | — | — | US | disclosed |
| US-4250174-A | 2-CARBAMATE AND 6-PHENYLTHIO OR PHENYLSULFINYL SUBSTITUTED, ANTHELMINTICS | MERCK & CO., INC. (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0018837-A1 | 3-Substituted imidazo (1,2-a) pyridines, their production, compositions containing them, and their use as anthelmintics | MERCK & CO. INC. (US) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | NPC1 987/4885RAB9A 1858/4885SMN1; SMN2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.